Nctid:
NCT06234527
Payload:
{"hasResults"=>false, "derivedSection"=>{"miscInfoModule"=>{"versionHolder"=>"2024-10-01"}, "conditionBrowseModule"=>{"meshes"=>[{"id"=>"D000017495", "term"=>"Hyperpigmentation"}], "ancestors"=>[{"id"=>"D000010859", "term"=>"Pigmentation Disorders"}, {"id"=>"D000012871", "term"=>"Skin Diseases"}], "browseLeaves"=>[{"id"=>"M21089", "name"=>"Facies", "relevance"=>"LOW"}, {"id"=>"M3512", "name"=>"Acne Vulgaris", "relevance"=>"LOW"}, {"id"=>"M19760", "name"=>"Hyperpigmentation", "asFound"=>"Hyperpigmentation", "relevance"=>"HIGH"}, {"id"=>"M10923", "name"=>"Lentigo", "relevance"=>"LOW"}, {"id"=>"M13754", "name"=>"Pigmentation Disorders", "relevance"=>"LOW"}, {"id"=>"M15674", "name"=>"Skin Diseases", "relevance"=>"LOW"}], "browseBranches"=>[{"name"=>"Symptoms and General Pathology", "abbrev"=>"BC23"}, {"name"=>"All Conditions", "abbrev"=>"All"}, {"name"=>"Skin and Connective Tissue Diseases", "abbrev"=>"BC17"}]}, "interventionBrowseModule"=>{"browseLeaves"=>[{"id"=>"M16255", "name"=>"Sunscreening Agents", "relevance"=>"LOW"}, {"id"=>"M10118", "name"=>"Immunoglobulin A", "relevance"=>"LOW"}], "browseBranches"=>[{"name"=>"Dermatologic Agents", "abbrev"=>"Derm"}, {"name"=>"All Drugs and Chemicals", "abbrev"=>"All"}]}}, "protocolSection"=>{"designModule"=>{"phases"=>["NA"], "studyType"=>"INTERVENTIONAL", "designInfo"=>{"allocation"=>"NON_RANDOMIZED", "maskingInfo"=>{"masking"=>"NONE"}, "primaryPurpose"=>"OTHER", "interventionModel"=>"PARALLEL"}, "enrollmentInfo"=>{"type"=>"ESTIMATED", "count"=>60}}, "statusModule"=>{"overallStatus"=>"NOT_YET_RECRUITING", "startDateStruct"=>{"date"=>"2024-02", "type"=>"ESTIMATED"}, "expandedAccessInfo"=>{"hasExpandedAccess"=>false}, "statusVerifiedDate"=>"2024-01", "completionDateStruct"=>{"date"=>"2024-08", "type"=>"ESTIMATED"}, "lastUpdateSubmitDate"=>"2024-01-30", "studyFirstSubmitDate"=>"2024-01-22", "studyFirstSubmitQcDate"=>"2024-01-30", "lastUpdatePostDateStruct"=>{"date"=>"2024-01-31", "type"=>"ACTUAL"}, "studyFirstPostDateStruct"=>{"date"=>"2024-01-31", "type"=>"ACTUAL"}, "primaryCompletionDateStruct"=>{"date"=>"2024-08", "type"=>"ESTIMATED"}}, "outcomesModule"=>{"primaryOutcomes"=>[{"measure"=>"IGA score for patients with melasma or acne induced post-inflammatory hyperpigmentation (PIHP)", "timeFrame"=>"from baseline to Day84", "description"=>"The hyperpigmentation is measured on a scale from 0 (cleared, almost cleared) to 3 (markedly darker than the surrounding normal skin)."}, {"measure"=>"modified Melasma Area and Severity Index (mMASI) for patients with melasma", "timeFrame"=>"from baseline to Day 84", "description"=>"the mMASI is calculated using 3 components: four regions (forehead, right malar, left malar and chin); area of involvement for each region (using a scale from 0 to 6); darkness compared to the surrounding normal skin for each area (evaluated using a scale from 0 to 6)."}, {"measure"=>"Post-Acne Hyperpigmentation Index (PAHPI)", "timeFrame"=>"from baseline to Day 84", "description"=>"The PAHPI total score is the sum of all 3 weighted scores: median lesion size (form 2 \\[\\< 3mm\\] to 8 \\[\\> 10mm\\], median lesion intensity (from 3 \\[slightly darker than surrounding skin\\] to 9 \\[significantly darker than surrounding skin\\] and number of lesions (from 1 \\[1-15\\] to 5 \\[\\> 60\\]. Total score ranges from 6 to 22."}, {"measure"=>"solar lentigo pigmentation scale", "timeFrame"=>"from baseline to Day84", "description"=>"The solar lentigo pigmentation scale evaluates the pigmentation using the following scale: from 0 (no pigmentation) to 10 (brown+)."}], "secondaryOutcomes"=>[{"measure"=>"colorimetry measurements", "timeFrame"=>"from baseline to Day84", "description"=>"Skin color is measured using the L\\*a\\*b\\* color space (L\\* represents lightness, a\\* its position between green and red, b\\* its position between blue and yellow)."}, {"measure"=>"stigmatization questionnaire", "timeFrame"=>"from baseline to Day84", "description"=>"The patients are asked to answer the 17 questions of the stigmatization questionnaire using six different responses: very often, often, sometimes, rarely, never, not concerned."}, {"measure"=>"local tolerability assessment by the investigator", "timeFrame"=>"Day28; Day56; Day84", "description"=>"The clinical signs (erythema, dryness and desquamation) are evaluated using 5-point rating scales: from 0 (no signs of irritation (no erythema/dryness/desquamation)) to 3 (severe signs of irritation (erythema/dryness/desquamation))."}, {"measure"=>"local tolerability assessment by the patient", "timeFrame"=>"Day28; Day56; Day84", "description"=>"the subjective symptoms (itching/tingling/burning sensation) are evaluated using 5-point rating scales: from 0 (no itching/tingling/burning sensation) to 3 (severe itching/tingling/burning sensation)."}]}, "oversightModule"=>{"oversightHasDmc"=>false, "isFdaRegulatedDrug"=>false, "isFdaRegulatedDevice"=>false}, "conditionsModule"=>{"keywords"=>["facial hyperpigmentation", "melasma", "acne induced PIHP", "solar lentigo"], "conditions"=>["Hyperpigmentation"]}, "descriptionModule"=>{"briefSummary"=>"The objective of this study is to evaluate the efficacy, cosmetic acceptability and improvement of the stigmatization of the tested product (2039125 03) used bis in die (BID) for 3 months in adult patients suffering from mild to moderate melasma, or mild to moderate acne induced post-inflammatory hyperpigmentation, or solar lentigo.", "detailedDescription"=>"Hyperpigmentation is a common skin condition in which the color of the skin becomes darker. These changes result from an excess of melanin production, distribution, or transport which can be caused by various internal and external factors such as genetic predisposition, hormonal changes, inflammation, acne, ultraviolet (UV) exposure.\n\nTypical hyperpigmentation disorders include post-inflammatory hyperpigmentation, melasma and solar lentigines.\n\nThis open, single-centre, three-arm study is carried out with a new cosmetic formulation developed with the aim of acting on facial hyperpigmentation and used under normal conditions of use with before/after comparisons.\n\nThis clinical trial is conducted in accordance with the protocol, the HELSINKI declaration (1964) and subsequent amendments, and/or the International Council on Harmonization (ICH) Good Clinical Practices (GCP)/ and in compliance with applicable regulatory requirements.\n\nStatistical Analysis:\n\n* Efficacy Analysis: in each group, the quantitative parameters are analyzed using a mixed-effect model. This model includes Time and baseline as fixed effects. Patient are added as random effect. The comparisons between post-baseline time-point and baseline are performed whatever the interaction results using a Dunnett adjustment. Degrees of freedom for the comparisons are approximated by the Kenward-Roger method.\n* Safety Analysis: no statistical analysis will be performed on safety. The data are presented descriptively.\n\nCategorical data are summarized using the number and percentage of patients in each category. Continuous data are summarized using the arithmetic mean, Standard Deviation (SD), Q1, Q3, minimum, median and maximum values.\n\nRegarding the sample size determination, there was no formal calculation. A number of 20 patients in each group (i.e. 60 patients in total) was considered sufficient to meet the study objective."}, "eligibilityModule"=>{"sex"=>"ALL", "stdAges"=>["ADULT", "OLDER_ADULT"], "minimumAge"=>"18 years", "healthyVolunteers"=>true, "eligibilityCriteria"=>"Inclusion Criteria:\n\n* all phototypes\n* only one of the following pigmentary conditions on the face: epidermal or mixed, mild to moderate melasma; mild to moderate acne-induced PIHP; solar lentigo\n* female patient of childbearing potential must use one of the reliable methods of contraception and agree not to change it during the study\n* patient agreeing not to be exposed to ultraviolet radiation (UV), natural (sun) or artificial (tanning salon), during the study\n\nExclusion Criteria:\n\n* female patient who gave birth less than 3 months prior to Day 0, who is pregnant, breast-feeding or who plans to become pregnant during the study\n* male patient with beard or facial hair, which would interfere with clinical evaluation or clinical procedure baseline)\n* patient with any inflammatory dermatosis of the face such as seborrheic dermatitis, rosacea etc.\n* severe melasma, dermal melasma\n* patient with facial pigmentary disorders other than those described in inclusion criteria\n* patient who has used topical depigmenting agents such as hydroquinone and derivatives, glycolic acid, kojic acid, retinoids and derivatives, azelaic acid, niacinamide within 1 month prior to Day 0/Baseline visit\n* patient who has used systemic treatments such as tranexamic acid and oral melatonin within 1 month prior to Day 0/Baseline visit;\n* patient who has used drugs inducing pigmentation such as tetracyclines, fluoroquinolones, antiepileptics within 1 month prior to Day 0/Baseline visit"}, "identificationModule"=>{"nctId"=>"NCT06234527", "briefTitle"=>"Efficacy and Tolerability of the Tested Formula After 3 Months of Treatment of Facial Hyperpigmentation of 3 Origins", "organization"=>{"class"=>"INDUSTRY", "fullName"=>"Cosmetique Active International"}, "officialTitle"=>"Evaluation of the Efficacy and Tolerability of the Tested Formula BID After 3 Months in the Treatment of Facial Hyperpigmentation of 3 Origins: Melasma, Acne Induced Post-Inflammatory Hyperpigmentation and Solar Lentigo", "orgStudyIdInfo"=>{"id"=>"LRP23021-D serum"}}, "armsInterventionsModule"=>{"armGroups"=>[{"type"=>"EXPERIMENTAL", "label"=>"mild to moderate melasma", "description"=>"adult patients suffering from mild to moderate melasma (Investigator's Global Assessment (IGA) 1 or 2)", "interventionNames"=>["Other: tested product"]}, {"type"=>"EXPERIMENTAL", "label"=>"mild to moderate acne induced PIHP", "description"=>"adult patients suffering from mild to moderate acne-induced PIHP (IGA 1 or 2) without active acne (i.e. less than 10 inflammatory lesions)", "interventionNames"=>["Other: tested product"]}, {"type"=>"EXPERIMENTAL", "label"=>"solar lentigo", "description"=>"adult patients suffering from solar lentigo with a pigmentation score \\> 5", "interventionNames"=>["Other: tested product"]}], "interventions"=>[{"name"=>"tested product", "type"=>"OTHER", "description"=>"application twice a day of the tested product (in the morning and evening) and a sunscreen (in the morning and at midday) to the face for 3 months", "armGroupLabels"=>["mild to moderate acne induced PIHP", "mild to moderate melasma", "solar lentigo"]}]}, "contactsLocationsModule"=>{"locations"=>[{"city"=>"Dakar", "country"=>"Senegal", "contacts"=>[{"name"=>"Fatimata LY", "role"=>"CONTACT", "email"=>"lyfaty@yahoo.fr", "phone"=>"+221 77 559 97 41"}], "facility"=>"Institut d'Hygiène Sociale de Dakar", "geoPoint"=>{"lat"=>14.6937, "lon"=>-17.44406}}], "centralContacts"=>[{"name"=>"Fatimata LY", "role"=>"CONTACT", "email"=>"lyfaty@yahoo.fr", "phone"=>"+221 77 559 97 41"}], "overallOfficials"=>[{"name"=>"Fatimata LY", "role"=>"PRINCIPAL_INVESTIGATOR", "affiliation"=>"INSTITUT D'HYGIENE SOCIALE DE DAKAR"}]}, "sponsorCollaboratorsModule"=>{"leadSponsor"=>{"name"=>"Cosmetique Active International", "class"=>"INDUSTRY"}, "responsibleParty"=>{"type"=>"SPONSOR"}}}}
